--- title: "Karyopharm Therap | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 35.07 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286410631.md" datetime: "2026-05-14T11:48:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286410631.md) - [en](https://longbridge.com/en/news/286410631.md) - [zh-HK](https://longbridge.com/zh-HK/news/286410631.md) --- # Karyopharm Therap | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 35.07 M Revenue: As of FY2026 Q1, the actual value is USD 35.07 M, beating the estimate of USD 31.4 M. EPS: As of FY2026 Q1, the actual value is USD -1.24, beating the estimate of USD -1.49. EBIT: As of FY2026 Q1, the actual value is USD -14.72 M. Karyopharm Therapeutics Inc. operates as a single segment focused on discovering, developing, and commercializing cancer drugs. #### Segment Revenue - **Product Revenue, net**: Increased to $29,163 thousand for the three months ended March 31, 2026, from $21,054 thousand for the same period in 2025, primarily due to an unusually high product return reserve in the prior year and lower gross-to-net discounts. - **License and Other Revenue**: Decreased to $5,903 thousand for the three months ended March 31, 2026, from $8,961 thousand for the same period in 2025, mainly due to a $7,000 thousand decrease in reimbursement revenue from Menarini, partially offset by a $3,500 thousand milestone payment from another licensing agreement. - **Total Revenue**: Increased to $35,066 thousand for the three months ended March 31, 2026, from $30,015 thousand for the same period in 2025. #### Operating Costs - **Cost of Sales**: Remained consistent at $1,345 thousand for the three months ended March 31, 2026, compared to $1,301 thousand for the same period in 2025. - **Research and Development (R&D) Expenses**: Remained relatively consistent at $33,797 thousand for the three months ended March 31, 2026, compared to $34,618 thousand for the same period in 2025. - **Selling, General and Administrative (SG&A) Expenses**: Remained relatively consistent at $26,684 thousand for the three months ended March 31, 2026, compared to $27,352 thousand for the same period in 2025. - **Total Operating Expenses**: Decreased to $61,826 thousand for the three months ended March 31, 2026, from $63,271 thousand for the same period in 2025. #### Operational Metrics - **Loss from Operations**: Improved to - $26,760 thousand for the three months ended March 31, 2026, from - $33,256 thousand for the same period in 2025. - **Total Other Income, net**: Decreased to $4,369 thousand for the three months ended March 31, 2026, from $9,830 thousand for the same period in 2025, primarily due to fair value remeasurement of embedded derivatives and liability-classified common stock warrants, and increased interest expense. - **Net Loss**: Improved to - $22,392 thousand for the three months ended March 31, 2026, from - $23,462 thousand for the same period in 2025. #### Cash Flow - **Net Cash Used in Operating Activities**: Decreased to - $22,728 thousand for the three months ended March 31, 2026, from - $38,984 thousand for the same period in 2025, primarily due to a $7,300 thousand decrease in interest and royalty payments. - **Net Cash Provided by Investing Activities**: Decreased to $3,200 thousand for the three months ended March 31, 2026, from $15,288 thousand for the same period in 2025, due to lower proceeds from maturities of investments. - **Net Cash Provided by Financing Activities**: Increased to $49,802 thousand for the three months ended March 31, 2026, from $0 thousand for the same period in 2025, primarily from common stock issuance under private placement and Open Market Sale Agreement. #### Future Outlook and Strategy As of March 31, 2026, Karyopharm Therapeutics Inc. had $90,900 thousand in cash and cash equivalents and an accumulated deficit of $1,800,000 thousand. The company’s existing liquidity is expected to fund current operating plans to late in the third quarter of 2026, though there is substantial doubt regarding its ability to continue as a going concern beyond one year without additional funding. Karyopharm Therapeutics Inc. anticipates reporting topline data from its Phase 3 XPORT-EC-042 trial in mid-2026 and from the SENTRY-2 and EMN29 trials in the second half of 2026, while also voluntarily withdrawing the accelerated approval for the DLBCL indication of XPOVIO, which will terminate related company-sponsored trials. ### Related Stocks - [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md) ## Related News & Research - [Karyopharm (KPTI) Leans on SENTRY in Pivotal Call](https://longbridge.com/en/news/287005767.md) - [RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)](https://longbridge.com/en/news/286559865.md) - [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)